Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability and population pharmacokinetics of oral nemonoxacin in community-acquired pneumonia (CAP) subjects.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TaiGen Biotechnology Co., Ltd.
• Treatments: Levofloxacin; Ofloxacin

Criteria

Inclusion Criteria:

1. age of 18~70, BMI ≥ 18 kg/m2

2. Female patients must avoid pregnancy

3. Patients who are clinically diagnosed with community-acquired pneumonia (CAP)

4. Chest X-ray shows inflammatory exudation or infiltration image.

5. Patients who used antibacterial agents (excluding quinolones) within 72 hours before

6. The patient's disease condition permits oral administration

Exclusion Criteria:

1. Patients who have any of bronchiectasis and pulmonary disease.

2. Hospitalized within 14 days before enrollment

3. Have a history of allergy to any quinolone or fluoroquinolone antibiotic

4. Patients who suffered uncontrolled mental disorders, epilepsy or central nervous system diseases.

5. Renal, liver insufficiency

6. Malabsorption syndrome or other gastrointestinal diseases

7. Immune system diseases,such as a history of human immunodeficiency virus (HIV) infection,neutropenia or malignant tumor in the blood system or a solid organ, or removal of spleen

8. Steroids longterm use, the dose is at least 20mg of prednisone daily

9. Patients under critical condition.

10. Shows significant abnormality of the cardiac conduction system (CCS) or other abnormalities, or prolonged QTc

11. Have a medical history of prolonged QTc, or require concomitant medication of drugs that will lead to prolongation of QTc

12. Patients who received chemotherapy or anti-tumor therapy within 6 months

13. Alcohol abused or drugs banned

14. Patients who used quinolones within two weeks before enrollment

15. Donated more than 500ml of blood within 3 months

16. co-medication of other antibacterial agents required.

17. by investigators judgement,patient who increase the risk to the subjects or interfere with this clinical trial.